54
Participants
Start Date
July 16, 2024
Primary Completion Date
April 30, 2028
Study Completion Date
June 30, 2028
Semaglutide Pen Injector
Escalated to 2.4mg or max tolerated dose
Placebo
Matched placebo.
RECRUITING
Yale Pediatric Diabetes Center, Adult and Children's Progam, New Haven
Collaborators (1)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Novo Nordisk A/S
INDUSTRY
Yale University
OTHER